Obinutuzumab Efficacy and Side Effects

Obinutuzumab approved by the U.S. Food and Drug Administration (FDA) in combination with chlorambucil for the treatment of previously untreated chronic lymphocytic leukemia Patients; in combination with bendamustine followed by octuzumab monotherapy for the treatment of patients with follicular lymphoma (FL) who have relapsed or been refractory after a rituximab-containing regimen.

Otuzumab is a fully human monoclonal antibody that binds to an epitope on CD20 that partially overlaps with the epitope recognized by rituximab. Cells that control protein glycosylation to produce Otuzumab were engineered to overexpress two glycosylation enzymes, MGAT3 and Golgi mannosidase, which reduce the amount of fucose that attaches to the antibody, which in turn increases the antibody's ability to activate natural killer cells. There are two black box warnings for otuzumab: hepatitis B reactivation and progressive multifocal leukoencephalopathy. In the pivotal clinical trial of otuzumab plus chlorambucil, clinical trial subjects experienced infusion reactions, neutropenia, thrombocytopenia, anemia, and fever and cough.

The original drug of Otuzumab has been launched in China and has entered the scope of medical insurance, but it is only reimbursed for patients who meet the indications. Specifications The price of 1000mg (40ml)*1 bottle may be around 9,000 yuan, which is a strictly controlled drug. The price of the Turkish version of Otuzumab Specifications1000mg/40ml per box listed overseas may be around RMB 10,000 (the price may fluctuate due to the exchange rate). The ingredients of the original drugs sold domestically and abroad are basically the same. There is currently no generic version of Otuzumab produced and launched. For more drug information and specific prices, please consult the medical consultant of Yaode.